Attached files

file filename
EX-99.1 - EX-99.1 - Anacor Pharmaceuticals, Inc.a12-23396_1ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 5, 2012

 

ANACOR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE

 

001-34973

 

25-1854385

(State of incorporation)

 

(Commission File No.)

 

(IRS Employer Identification No.)

 

1020 East Meadow Circle

Palo Alto, CA 94303-4230

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (650) 543-7500

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

ITEM 8.01

 

OTHER EVENTS.

 

On October 5, 2012, Anacor Pharmaceuticals, Inc. issued a press release announcing that its collaboration partner GlaxoSmithKline has discontinued clinical development of GSK2251052.

 

A copy of this press release is attached as Exhibit 99.1, and is incorporated herein by reference.

 

ITEM 9.01

 

FINANCIAL STATEMENTS AND EXHIBITS.

 

(d)     Exhibits.

 

Exhibit Number

 

Description

99.1

 

Press Release titled “Anacor Pharmaceuticals Announces that GSK has Discontinued Clinical Development of GSK2251052,” dated October 5, 2012

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: October 9, 2012

ANACOR PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ Geoffrey M. Parker

 

 

Geoffrey M. Parker

 

 

Senior Vice President, Chief Financial Officer

 

3



 

INDEX TO EXHIBITS

 

Exhibit Number

 

Description

99.1

 

Press Release titled “Anacor Pharmaceuticals Announces that GSK has Discontinued Clinical Development of GSK2251052,” dated October 5, 2012

 

4